Your browser doesn't support javascript.
loading
A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients
Lanzafame, Massimiliano; Bonora, Stefano; Lattuada, Emanuela; Calcagno, Andrea; Vento, Sandro.
Afiliação
  • Lanzafame, Massimiliano; G.B. Rossi Hospital. Infectious Diseases Unit. IT
  • Bonora, Stefano; University of Torino. Department of Infectious Diseases. IT
  • Lattuada, Emanuela; G.B. Rossi Hospital. Infectious Diseases Unit. IT
  • Calcagno, Andrea; University of Torino. Department of Infectious Diseases. IT
  • Vento, Sandro; University of Botswana. Faculty of Medicine and Health Sciences. Department of Internal Medicine. Gaborone. BW
Braz. j. infect. dis ; 15(5): 498-500, Sept.-Oct. 2011.
Article em En | LILACS | ID: lil-612714
Biblioteca responsável: BR1.1
ABSTRACT
Darunavir (DRV) is an HIV-1 protease inhibitor that is used together with a low boosting dose of ritonavir as part of an antiretroviral therapy (ART) regimen in treatment-experienced and naïve HIVpositive patients. In naïve and experienced patients with no DRV-mutations, DRV is licensed at the dose of 800 mg plus 100 mg of ritonavir once daily. We report our results in seven ART-experienced HIV-infected patients, in whom a reduced dose of darunavir/ritonavir (600/100 mg once daily) successfully controlled viral replication.
Assuntos
Palavras-chave

Texto completo: 1 Índice: LILACS Assunto principal: Sulfonamidas / Infecções por HIV / Inibidores da Protease de HIV / Ritonavir Limite: Adult / Female / Humans / Male Idioma: En Revista: Braz. j. infect. dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2011 Tipo de documento: Article

Texto completo: 1 Índice: LILACS Assunto principal: Sulfonamidas / Infecções por HIV / Inibidores da Protease de HIV / Ritonavir Limite: Adult / Female / Humans / Male Idioma: En Revista: Braz. j. infect. dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2011 Tipo de documento: Article